mobile.zenopa.com Homepage Homepage
Employment Role Location
Business Sector Advanced  
Phone 01494 818 000
Current Jobs

Sales Specialist
Location: North East

Product Manager
Location: West Yorkshire

Territory Manager - Sports Medicine
Location: M62 Corridor

Regional Business Manager
Location: North East Region

Sales Specialist - PAS
Location: North East

Expert Trainer
Location: Mid UK

Field Sales Coach - Central
Location: Central UK

Senior Brand Manager
Location: Welwyn Garden City

Territory Manager - Sports Medicine
Location: South Central

Sales Specialist - MSS
Location: West Midlands

Centralised Diagnostics Sales Specialist
Location: South and Central London

Medical Advisor
Location: Princes Risborough, Bucks

Training Manager - Renal & Neurology and ELearnin
Location: Maidenhead, Berks

Training Manager - Part-time
Location: Maidenhead

Territory Manager - Sports Medicine
Location: West Scotland

Boehringer Ingelheim announces results of Transcend trial

Posted on 01/09/2008 in Pharmaceutical Company Product News

Boehringer Ingelheim has announced the results of the Transcend trial of Micardis (telmisartan), with the compound reducing the risk of heart attack, stroke and cardiovascular death in ACE-intolerant patients deemed to be at high risk.

The results were presented at the annual meeting of the European Society of Cardiology in Munich, Germany.

In the study, patients treated with Micardis 80mg showed a 13 per cent reduction in risk of cardiovascular death, myocardial infarction and stroke compared to those already receiving best standard of care.

Furthermore, a non-statistically significant eight per cent reduction of the composite of cardiovascular death, stroke, myocardial infarction and congestive heart failure hospitalisation was seen in the trial.

Professor Salim Yusuf, director of the Population Health Research Institute at McMaster University, Hamilton, Canada, said: "Earlier this year, the Ontarget trial showed that telmisartan is as protective as, but better tolerated than the ACE-inhibitor ramipril."

He added the results from the Transcend trial show moderate but vital progress for high-risk patients who are intolerant to ACE inhibitors.

In June 2008, Boehringer Ingelheim announced the results of two trials showing treatment regimens based on Micardis can help more patients attain their blood pressure goals.

Other news stories from 01/09/2008

Read more in the Zenopa News Archive

How this news is generated

Mark Denton
Managing Director


Pharmaceutical Sales Jobs | Pharmaceutical Executive Jobs | Pharmaceutical Marketing Jobs | Medical Sales Jobs | Medical Devices Marketing Jobs | Medical Executive Jobs
Dental Sales Jobs | Veterinary Sales Jobs | Scientific Sales Jobs | Consumer Healthcare Sales Jobs | Consumer Healthcare Management Jobs | Medical Writing Jobs
Medical Writer Jobs | Healthcare PR Jobs | Animal Health Sales Jobs

home | our clients | browse news | browse jobs | links | hotel directory | Valid HTML | copyright © 2012 Zenopa Ltd | terms & conditions of use